Alejandra Castanon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alejandra Castanon has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Peter Sasieni
Queen Mary University of London
48 shared publications - Rebecca Landy
Surveillance, Prevention, and Health Services Research American Cancer Society Atlanta Georgia USA
18 shared publications - Anita Wey Wey Lim
School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, SE1 9RT, UK
6 shared publications Francesca Pesola
School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK
5 shared publications- Matejka Rebolj
Queen Mary University of London
5 shared publications Jack Cuzick
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
4 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0359861
Measurement error adjusted prevalence of undiagnosed hypertension in England: A cross-sectional study
Background: Hypertension case-finding and management is key to reducing premature morbidity and mortality. In England, 14.8% of people receive treatment for hypertension but the total number of hypertensive individuals remains unclear, as it can only be estimated statistically. This study aimed to estimate how many individuals aged 40 + may unknowingly have hypertension by accounting for differences between clinic and out-of-office blood pressure readings. Methods: We analysed individual-level data from the 2017–2019 Health Survey for England (HSE), including individuals aged ≥40 without a hypertension diagnosis. A validated algorithm (Predicting Out-of-Office Blood Pressure- PROOF-BP) was applied to estimate likely out-of-office measurements. Observed BP was defined as the mean of the second and third measurement taken at an HSE visit. Predicted hypertension was calculated using PROOF-BP and observed hypertension using actual clinic measurements. We explored a diagnostic threshold for predicted (out-of-office) hypertension of ≥135/85 mmHg (primary outcome) and of ≥140/90 mmHg (secondary outcome). Weighted hypertension prevalence estimates are presented by age, sex and geographical region. National population statistics were used to extrapolate results to the English population. Results: The observed prevalence of undiagnosed hypertension in the study population was 27.7% (95% Confidence Interval [CI]:26.4%−29.1%). The predicted prevalence after adjustment was 21.8% (95%CI:20.6%−23.0%). Predicted prevalence was nearly double in males (29.8%, 95%CI:27.8%−32.0%) compared to females (14.6%, 95%CI:13.3%−15.9%) and varied by region: West Midlands (26.3%, 95%CI:22.2%−31.0%), London (16.9%, 95%CI:13.5%−20.9%). Extrapolating estimates to the total population aged ≥40 in England we estimate approximately 4.2 million people in England are unaware of their hypertension. Of these we estimate that over 2.9 million could be newly diagnosed by the current diagnostic pathway. Conclusions: Over 4 million people in England are estimated to have undiagnosed hypertension. This study’s refined analytical approach provides a more precise estimate of this population, supporting targeted public health initiatives to identify and address undiagnosed cases.
- 27 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0359861
Open AccessMeasurement error adjusted prevalence of undiagnosed hypertension in England: A cross-sectional study
Background: Hypertension case-finding and management is key to reducing premature morbidity and mortality. In England, 14.8% of people receive treatment for hypertension but the total number of hypertensive individuals remains unclear, as it can only be estimated statistically. This study aimed to estimate how many individuals aged 40 + may unknowingly have hypertension by accounting for differences between clinic and out-of-office blood pressure readings. Methods: We analysed individual-level data from the 2017–2019 Health Survey for England (HSE), including individuals aged ≥40 without a hypertension diagnosis. A validated algorithm (Predicting Out-of-Office Blood Pressure- PROOF-BP) was applied to estimate likely out-of-office measurements. Observed BP was defined as the mean of the second and third measurement taken at an HSE visit. Predicted hypertension was calculated using PROOF-BP and observed hypertension using actual clinic measurements. We explored a diagnostic threshold for predicted (out-of-office) hypertension of ≥135/85 mmHg (primary outcome) and of ≥140/90 mmHg (secondary outcome). Weighted hypertension prevalence estimates are presented by age, sex and geographical region. National population statistics were used to extrapolate results to the English population. Results: The observed prevalence of undiagnosed hypertension in the study population was 27.7% (95% Confidence Interval [CI]:26.4%−29.1%). The predicted prevalence after adjustment was 21.8% (95%CI:20.6%−23.0%). Predicted prevalence was nearly double in males (29.8%, 95%CI:27.8%−32.0%) compared to females (14.6%, 95%CI:13.3%−15.9%) and varied by region: West Midlands (26.3%, 95%CI:22.2%−31.0%), London (16.9%, 95%CI:13.5%−20.9%). Extrapolating estimates to the total population aged ≥40 in England we estimate approximately 4.2 million people in England are unaware of their hypertension. Of these we estimate that over 2.9 million could be newly diagnosed by the current diagnostic pathway. Conclusions: Over 4 million people in England are estimated to have undiagnosed hypertension. This study’s refined analytical approach provides a more precise estimate of this population, supporting targeted public health initiatives to identify and address undiagnosed cases.
- Open Access
Impact of COVID-19 infection on social care use in people over 50 years of age: a matched cohort study in North-West London
Objectives To estimate the impact of COVID-19 infection on the requirement for social care services among adults aged ≥50 years in North-West London. Design Population-based matched cohort study using linked routinely collected electronic social care, primary care and hospital records (the Discover dataset). Setting Approximately 4.7 million people with a general practitioner record in North-West London. Participants 150 654 adults aged ≥50 years with a first diagnosis of COVID-19 between January 2020 and February 2023 and 547 704 propensity score matched comparators without a COVID-19 diagnosis during the same period. Main outcome measures Social care use and associated costs overall and by specific type (care home, domiciliary care, respite care, social care assessments) stratified by age group, index year, diagnosis setting, severe COVID-19 risk status, frailty and care home admission prior to index. Overall survival was also assessed. Results A total of 9174 (6.09%) individuals with COVID-19 required social care use (of any type) during follow-up, 2.54 times (95% CI 2.48 to 2.61; pConclusions COVID-19 infection is associated with meaningfully higher social care requirements in the ≥50 years population. Reducing the need for social care use and the associated costs of care should be one of the goals of interventions to reduce the risk and severity of COVID-19 infection.
Open AccessImpact of COVID-19 infection on social care use in people over 50 years of age: a matched cohort study in North-West London
Objectives To estimate the impact of COVID-19 infection on the requirement for social care services among adults aged ≥50 years in North-West London. Design Population-based matched cohort study using linked routinely collected electronic social care, primary care and hospital records (the Discover dataset). Setting Approximately 4.7 million people with a general practitioner record in North-West London. Participants 150 654 adults aged ≥50 years with a first diagnosis of COVID-19 between January 2020 and February 2023 and 547 704 propensity score matched comparators without a COVID-19 diagnosis during the same period. Main outcome measures Social care use and associated costs overall and by specific type (care home, domiciliary care, respite care, social care assessments) stratified by age group, index year, diagnosis setting, severe COVID-19 risk status, frailty and care home admission prior to index. Overall survival was also assessed. Results A total of 9174 (6.09%) individuals with COVID-19 required social care use (of any type) during follow-up, 2.54 times (95% CI 2.48 to 2.61; pConclusions COVID-19 infection is associated with meaningfully higher social care requirements in the ≥50 years population. Reducing the need for social care use and the associated costs of care should be one of the goals of interventions to reduce the risk and severity of COVID-19 infection.
- Open Access
- 10 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 49, 101157
Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006–2020: a population-based trends analysis
- 10 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 49, 101157
Open AccessAssociation between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006–2020: a population-based trends analysis
- Open Access
- 27 January 2023
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 38, 101182
audit_cc: A Stata command for the analysis of matched case-control audits of cervical cancer screening
- 27 January 2023
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 38, 101182
Open Accessaudit_cc: A Stata command for the analysis of matched case-control audits of cervical cancer screening
- Open Access
Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions
Background We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. Methods We used three CC models to project the short- and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2- or 5-year delay) versus no delay, in the context of both cytology-based and HPV-based screening. Results Models projected a relative increase in symptomatically-detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard) and 170% higher (MISCAN-Cervix) for under-screened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen three years prior to disruption). Over a woman’s lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman’s last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners Conclusions Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect under-screened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions. Funding This study was supported by funding from the National Cancer Institute (U01CA199334). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Megan A Smith receives salary support from the National Health and Medical Research Council, Australia (APP1159491) and Cancer Institute NSW (ECF181561). Matejka Rebolj is funded by Cancer Research UK (reference: C8162/A27047). James O’Mahony is funded by Ireland’s Health Research Board (EIA2017054). Karen Canfell receives salary support from the National Health and Medical Research Council, Australia (APP1194679). Emily A. Burger receives salary support from the Norwegian Cancer Society.
Open AccessHealth impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions
Background We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. Methods We used three CC models to project the short- and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2- or 5-year delay) versus no delay, in the context of both cytology-based and HPV-based screening. Results Models projected a relative increase in symptomatically-detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard) and 170% higher (MISCAN-Cervix) for under-screened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen three years prior to disruption). Over a woman’s lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman’s last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners Conclusions Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect under-screened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions. Funding This study was supported by funding from the National Cancer Institute (U01CA199334). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Megan A Smith receives salary support from the National Health and Medical Research Council, Australia (APP1159491) and Cancer Institute NSW (ECF181561). Matejka Rebolj is funded by Cancer Research UK (reference: C8162/A27047). James O’Mahony is funded by Ireland’s Health Research Board (EIA2017054). Karen Canfell receives salary support from the National Health and Medical Research Council, Australia (APP1194679). Emily A. Burger receives salary support from the Norwegian Cancer Society.
- 20 June 2022
- Published by Elsevier in Public Health
- Vol. 222, e1-e2
As the pandemic evolves, so must global monitoring of COVID-19
- 20 June 2022
- Published by Elsevier in Public Health
- Vol. 222, e1-e2
As the pandemic evolves, so must global monitoring of COVID-19
- 19 May 2022
- Published by Elsevier in The Lancet
- Vol. 399 (10339) , 1940
HPV vaccination and cervical cancer screening – Authors' reply
- 19 May 2022
- Published by Elsevier in The Lancet
- Vol. 399 (10339) , 1940
HPV vaccination and cervical cancer screening – Authors' reply
- Open Access
- 16 May 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (9) , 1262-1269
Benefit of Biennial Fecal Occult Blood Screening on Colorectal Cancer in England: A Population-Based Case-Control Study
Background: The English national bowel cancer screening program offering a guaiac fecal occult blood test began in July 2006. In randomized controlled trials of guaiac fecal occult blood test screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the national bowel cancer screening program on stage-specific CRC incidence as a likely precursor of a mortality effect. Methods: In this population-based case-control study, cases were individuals diagnosed with CRC aged 60-79 years between January 1, 2012, and December 31, 2013. Two controls per case were matched on geographic region, gender, date of birth, and year of first screening invitation. Screening histories were extracted from the screening database. Conditional logistic regression with correction for self-selection bias was used to estimate odds ratios (odds ratios corrected for self-selection bias [cOR]) and 95% confidence intervals (CIs) by Duke stage, sex, and age. Results: 14 636 individuals with CRC and 29 036 without were eligible for analysis. The odds of CRC (any stage) were increased within 30 days of a screening test and decreased thereafter. No reduction in CRC (any stage) among screened individuals compared with those not screened was observed (cOR = 1.00, 95% CI = 0.89 to 1.15). However, screened individuals had lower odds of Duke stage D CRC (cOR = 0.68, 95% CI = 0.50 to 0.93). We estimate 435 fewer Duke D CRC by age 80 years in 100 000 people screened biennially between ages 60 and 74 years compared with an unscreened cohort. Conclusion: The impact of colorectal screening on advanced CRC incidence suggests that the program will meet its aim of reducing mortality.
- 16 May 2022
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 114 (9) , 1262-1269
Open AccessBenefit of Biennial Fecal Occult Blood Screening on Colorectal Cancer in England: A Population-Based Case-Control Study
Background: The English national bowel cancer screening program offering a guaiac fecal occult blood test began in July 2006. In randomized controlled trials of guaiac fecal occult blood test screening, reductions in mortality were accompanied by reductions in advanced stage colorectal cancer (CRC). We aimed to evaluate the effect of participation in the national bowel cancer screening program on stage-specific CRC incidence as a likely precursor of a mortality effect. Methods: In this population-based case-control study, cases were individuals diagnosed with CRC aged 60-79 years between January 1, 2012, and December 31, 2013. Two controls per case were matched on geographic region, gender, date of birth, and year of first screening invitation. Screening histories were extracted from the screening database. Conditional logistic regression with correction for self-selection bias was used to estimate odds ratios (odds ratios corrected for self-selection bias [cOR]) and 95% confidence intervals (CIs) by Duke stage, sex, and age. Results: 14 636 individuals with CRC and 29 036 without were eligible for analysis. The odds of CRC (any stage) were increased within 30 days of a screening test and decreased thereafter. No reduction in CRC (any stage) among screened individuals compared with those not screened was observed (cOR = 1.00, 95% CI = 0.89 to 1.15). However, screened individuals had lower odds of Duke stage D CRC (cOR = 0.68, 95% CI = 0.50 to 0.93). We estimate 435 fewer Duke D CRC by age 80 years in 100 000 people screened biennially between ages 60 and 74 years compared with an unscreened cohort. Conclusion: The impact of colorectal screening on advanced CRC incidence suggests that the program will meet its aim of reducing mortality.
- Open Access
- 4 April 2022
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 29 (3) , 203-208
COVID-19 disruption to cervical cancer screening in England
Introduction: In England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC). Methods: Using Public Health England CC screening data on laboratory samples received in 2018 as a baseline we quantify the reduction in screening attendances due to the COVID-19 pandemic between April 2020 and March 2021 for women aged 25–64. We model the impact on excess CC diagnoses assuming once invitations resume 87.5% of women attend within 12 months and 12.5% delay screening for 3 or 5 years (depending on age). Results: The number of samples received at laboratories was 91% lower than expected during April, 85% during May and 43% during June 2020 compared to the same period in 2018. Although on average laboratories received 12.6% more samples between August 2020 and April 2021 than over the same months in 2018, by April 2021 there was a short fall of 200,949 samples (6.4% fewer than in 2018). An excess of 41 CC (4.0 per 100,000 women with a maximum screening delay of 12 months) are predicted to occur among the estimated 1,024,794 women attending this screening round with a delay. An excess of 60 CC (41.0 per 100,000 women) are predicted to occur among the estimated 146,391 women who do not attend this screening round. Conclusion: Prompt restoration of cervical screening services limited the impact on excess CC diagnoses. However, in 2020 a 6.4% shortfall of screening samples was observed. Every effort should be made to reassure these women that services are open and safe to attend.
- 4 April 2022
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 29 (3) , 203-208
Open AccessCOVID-19 disruption to cervical cancer screening in England
Introduction: In England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC). Methods: Using Public Health England CC screening data on laboratory samples received in 2018 as a baseline we quantify the reduction in screening attendances due to the COVID-19 pandemic between April 2020 and March 2021 for women aged 25–64. We model the impact on excess CC diagnoses assuming once invitations resume 87.5% of women attend within 12 months and 12.5% delay screening for 3 or 5 years (depending on age). Results: The number of samples received at laboratories was 91% lower than expected during April, 85% during May and 43% during June 2020 compared to the same period in 2018. Although on average laboratories received 12.6% more samples between August 2020 and April 2021 than over the same months in 2018, by April 2021 there was a short fall of 200,949 samples (6.4% fewer than in 2018). An excess of 41 CC (4.0 per 100,000 women with a maximum screening delay of 12 months) are predicted to occur among the estimated 1,024,794 women attending this screening round with a delay. An excess of 60 CC (41.0 per 100,000 women) are predicted to occur among the estimated 146,391 women who do not attend this screening round. Conclusion: Prompt restoration of cervical screening services limited the impact on excess CC diagnoses. However, in 2020 a 6.4% shortfall of screening samples was observed. Every effort should be made to reassure these women that services are open and safe to attend.
- Open Access
- 12 December 2021
- Published by Wiley in International Journal of Cancer
- Vol. 150 (9) , 1412-1421
Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study
Several international cervical screening guidelines advise against using high‐risk human papillomavirus (HR‐HPV) testing in women younger than 30. The rationale for this in young women, lies in the potential for additional detection of both low‐grade and high‐grade cervical intraepithelial neoplasia (CIN) leading to unnecessary treatments without reducing the burden of cervical cancer. We studied 56 544 women screened at 24 to 29 with HR‐HPV testing and 116 858 screened with liquid‐based cytology (LBC) in the English HPV screening pilot. They were compared to 528 460 women screened at the age of 30 to 49. We studied the detection of cervical cancer and CIN2/3 across two consecutive screening rounds 3 years apart. At 24 to 29, a positive HR‐HPV test detected more cases of cervical cancer in the prevalence round than did a positive LBC test (1.36/1000 screened vs 0.82/1000, ORadj: 1.61, 95% CI: 1.18‐2.19). In women with a negative HR‐HPV test, cervical cancer was diagnosed before or at the incidence round in 0.07/1000. After a negative LBC test, cancer detection reached 0.47/1000 and 40% of these cases were diagnosed at FIGO stage IB+. HR‐HPV testing increased the detection of CIN2/3 diagnoses in two consecutive rounds combined by 30% (71.9/1000 vs 55.2/1000). The patterns of detection of cervical cancer and CIN2/3 were almost identical at older ages. These data support using HR‐HPV testing for screening of women younger than 30, which not only accelerates the diagnosis of cervical cancer but leads to a similar relative increase in CIN2/3 diagnosis to that found in women aged 30 to 49.
- 12 December 2021
- Published by Wiley in International Journal of Cancer
- Vol. 150 (9) , 1412-1421
Open AccessAcceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study
Several international cervical screening guidelines advise against using high‐risk human papillomavirus (HR‐HPV) testing in women younger than 30. The rationale for this in young women, lies in the potential for additional detection of both low‐grade and high‐grade cervical intraepithelial neoplasia (CIN) leading to unnecessary treatments without reducing the burden of cervical cancer. We studied 56 544 women screened at 24 to 29 with HR‐HPV testing and 116 858 screened with liquid‐based cytology (LBC) in the English HPV screening pilot. They were compared to 528 460 women screened at the age of 30 to 49. We studied the detection of cervical cancer and CIN2/3 across two consecutive screening rounds 3 years apart. At 24 to 29, a positive HR‐HPV test detected more cases of cervical cancer in the prevalence round than did a positive LBC test (1.36/1000 screened vs 0.82/1000, ORadj: 1.61, 95% CI: 1.18‐2.19). In women with a negative HR‐HPV test, cervical cancer was diagnosed before or at the incidence round in 0.07/1000. After a negative LBC test, cancer detection reached 0.47/1000 and 40% of these cases were diagnosed at FIGO stage IB+. HR‐HPV testing increased the detection of CIN2/3 diagnoses in two consecutive rounds combined by 30% (71.9/1000 vs 55.2/1000). The patterns of detection of cervical cancer and CIN2/3 were almost identical at older ages. These data support using HR‐HPV testing for screening of women younger than 30, which not only accelerates the diagnosis of cervical cancer but leads to a similar relative increase in CIN2/3 diagnosis to that found in women aged 30 to 49.